John Theurer Cancer Center 

Tackle Prostate Cancer with Harry Carson: © stock.adobe.com.

This Prostate Cancer Awareness Month, join our free Men's Health Event where Hall of Famer Harry Carson will reveal his own recent and powerful story of tackling a cancer diagnosis - a journey he's sharing to encourage all men to take charge of their health and get screened.

https://www.youtube.com/watch?app=desktop&v=SzJ7Lp3v4Uc

: Join John Theurer Cancer Center’s Community Outreach & Engagement team and Hackensack University Medical Center's Urology experts for a free Men's Health Fair offering vital health screenings for prostate cancer, as well as other chronic conditions like high blood pressure, diabetes, asthma, lung disease, colorectal cancer and more.

This event is particularly important for individuals at a higher risk for prostate cancer, including African American men and those with a family history of the disease.

New York Giants legend Harry Carson will attend this event to share opening remarks on the importance of screenings, and reveal details of his own recent cancer journey.

About 1 in 8 men will be diagnosed with prostate cancer during his lifetime. African American men are at an even greater risk for developing prostate cancer over white men and other men of color. According to the Centers for Disease Control and Prevention, out of every 100 American men, about 13 will get prostate cancer during their lifetime, and about 2 to 3 men will die from prostate cancer. African American men are more than twice as likely to die from prostate cancer than other men and are also slightly more likely than white men to be diagnosed with advanced disease. Men who are at higher risk of prostate cancer, including those with a family history, will benefit most from this event. 

Articles

Prostate Cancer Awareness Month features a free Men's Health Event with Hall of Famer Harry Carson sharing his cancer journey to promote health screenings. The event, organized by John Theurer Cancer Center and Hackensack University Medical Center, offers screenings for prostate cancer and other chronic conditions. It targets high-risk groups, including African American men and those with a family history of prostate cancer. Statistics highlight the increased risk and mortality rates for African American men, emphasizing the importance of early detection and regular screenings.

This Prostate Cancer Awareness Month, join our free Men's Health Event.

Tackle Prostate Cancer with New York Giants Legend Harry Carson and Hackensack Meridian Health

John Frotton, a 66-year-old chemical engineer from East Stroudsburg, Pennsylvania.

For John Frotton, a 66-year-old chemical engineer from East Stroudsburg, Pennsylvania, numbers are a way of life. He spends his days working on complex projects, converting waste streams into new forms of energy. But a year ago, a few simple numbers changed his life forever.

His PSA, a key marker for prostate health, had always been normal, sitting comfortably under 3. Then, in less than a year, it shot up to 9.

The diagnosis that followed was one that millions of men fear: aggressive prostate cancer.

"When you hear the word 'aggressive,' it's a shock to the system," John might say. The standard treatment plan was clear and immediate: a radical prostatectomy to surgically remove the prostate and some surrounding lymph nodes.

But even with the best surgery, a shadow of uncertainty often remains. For men with high-risk cancer, the chance of the disease returning can be as high as 40% within a decade. It’s a statistic that can weigh heavily on a patient's mind.

This is where John’s story takes a pioneering turn. He was offered a chance to fight the cancer 

 it was even removed. He became the very first patient to enroll in the PRELUDE Trial, a groundbreaking clinical study aimed at preventing recurrence.

Led by Dr. Nitin Yerram, co-director of urologic oncology at the renowned John Theurer Cancer Center (JTCC), the trial represents a paradigm shift in treatment. “We are dedicated to advancing the treatment of prostate cancer and proud to be the first center in North America to conduct this innovative clinical trial,” said Dr. Yerram.

Executing such a sophisticated treatment requires a seamless, multidisciplinary approach. For the PRELUDE trial, this means a dedicated team of specialists from Urologic Oncology, Nuclear Medicine, and Radiation Oncology work in close collaboration. The nuclear medicine team is responsible for the precise preparation and administration of the radiopharmaceutical, while radiation oncologists provide expertise on its therapeutic effects. This integrated effort is so specialized that Hackensack University Medical Center is currently the only institution where urologists can offer patients this proactive treatment, solidifying its position as a leader in prostate cancer care.

The PRELUDE Trial is testing a powerful, FDA-approved therapy called Lu-177-PSMA-617 in a new way. Instead of being used for cancer that has already spread, it’s being given to men like John 

Think of it as a microscopic heat-seeking missile. The therapy contains two parts: a molecule that targets a protein (PSMA) found almost exclusively on prostate cancer cells, and a radioactive particle (Lu-177) that delivers a precise dose of radiation. The drug travels through the body, locks onto the cancer cells, and destroys them, while minimizing harm to healthy tissue. The goal is to eliminate any microscopic cells that might have escaped the prostate, effectively stopping a recurrence before it can even start.

As the first participant, John received two cycles of the therapy, six weeks apart, before undergoing his scheduled prostatectomy.

Today, John is back in his home office, feeling well and looking forward to a trip to Philadelphia. He recently attended a high school reunion where he met a former classmate who had gone through a similar prostate cancer diagnosis. The conversation was a powerful reminder of his unique journey—one man had followed the standard path, while John was helping to forge a new one.

Being the first has given him more than just a novel treatment; it has given him peace of mind. He is proud to be a pioneer in a study that could change the future for countless men.

John’s story is a powerful testament to two critical things:

The Lifesaving Importance of Screening: His rapidly rising PSA was the alarm bell that allowed for early, decisive action. It’s a reminder for all men to stay on top of their health and get regular check-ups.

The Power of Medical Innovation: Clinical trials like PRELUDE are the engine of progress. They offer patients access to the next generation of care and give hope where there was once uncertainty.

“We are eager to see if this promising therapy improves patient outcomes in men with high-risk localized prostate cancer,” Dr. Yerram stated.

For John Frotton and the men who will follow him, this trial is more than just a study. It’s a prelude to a future with less fear and a greater chance for a long, healthy life.

This Prostate Cancer Awareness Month, please consider sharing the news of this crucial trial.

John Frotton, a 66-year-old chemical engineer, faced an aggressive prostate cancer diagnosis after a significant rise in his PSA levels. He became the first participant in the PRELUDE Trial, a groundbreaking study using Lu-177-PSMA-617 therapy before surgery to prevent cancer recurrence. This trial, led by Dr. Nitin Yerram at Hackensack University Medical Center, represents a paradigm shift in prostate cancer treatment. John's experience underscores the importance of regular health screenings and the potential of innovative clinical trials to improve patient outcomes.

This Prostate Cancer Awareness Month, a first-in-the-nation trial offers hope by using a targeted therapy before surgery to stop recurrence in its tracks.

A Prelude to a Cure: How One Man’s Courage is Redefining the Fight Against Prostate Cancer

Members of the Department of Urology at Hackensack University Medical Center have launched the Kidney Cancer Resource Center.

Members of the Department of Urology at Hackensack University Medical Center have launched the Kidney Cancer Resource Center, an online educational tool for people diagnosed with renal cell carcinoma, a type of kidney cancer. The website provides information to help them better understand the disease and make treatment decisions based on the findings of the latest research.

The Kidney Cancer Resource Center is funded by a grant from Pfizer Inc. to support approaches designed to improve patient outcomes. "This website helps people with kidney cancer expand their understanding of this disease and links them with the most effective care," said Nitin Yerram, MD, co-director of Urologic Oncology at John Theurer Cancer Center — part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University — and director of Urologic Research. Dr. Yerram spearheaded the development of the website.

In addition to surgery, patients with renal cell cancer have numerous treatment options, including chemotherapy, targeted therapies, and immunotherapies. Dr. Yerram and his colleagues designed an educational curriculum that features videos with team members as well as other resources to help patients newly diagnosed with localized or metastatic kidney cancer navigate their treatment options, learn what to expect, and connect with support

The website is a collaborative effort by Hackensack Meridian 

’s leading experts in the field of renal cell carcinoma, including surgeons, medical and radiation oncologists, cancer researchers, palliative care providers, and more. Its purpose is to guide patients and their friends, family members, and caregivers through the cancer care journey. Viewers can learn about:

What kidney cancer is and the different types of the disease

Care team members and their respective roles in patient care

What to expect when living with kidney cancer

The site is accessible to current patients as well as members of the community who are not yet patients at Hackensack University Medical Center. "This website provides a consolidated way for patients to better understand kidney cancer so they can make more informed decisions about their care when they meet with their doctors," said Dr. Yerram. "Recognizing that information is power, the goal is to empower those impacted by kidney cancer with a thorough understanding of the disease."

"When someone hears they have renal cell carcinoma, it can be daunting to know which treatment options are most appropriate," noted Michael D. Stifelman, MD, professor and chair of Urology at Hackensack University Medical Center. "Our Urology program has some of the highest volumes and strongest outcomes in treating kidney cancer surgically, but surgery is just one option and only part of the patient’s journey. This program makes that decision-making process much easier to navigate."

The Kidney Cancer Resource Center, developed by Hackensack University Medical Center's Department of Urology, is an online educational platform for renal cell carcinoma patients. Funded by Pfizer Inc., it aims to enhance patient outcomes by providing comprehensive information on kidney cancer, including diagnosis, treatment options, and clinical trials. The resource is a collaborative effort involving experts across various specialties, offering videos and educational materials to guide patients and their support networks. It empowers patients to make informed decisions about their care and treatment journey.

John Theurer Cancer Center

Tackle Prostate Cancer with New York Giants Legend Harry Carson and Hackensack Meridian Health

A Prelude to a Cure: How One Man’s Courage is Redefining the Fight Against Prostate Cancer

Hackensack University Medical Center Launches Educational Website for People with Kidney Cancer

Latest News